Stress, Sex, and the Generalization of Fear
2 other identifiers
interventional
606
1 country
1
Brief Summary
The impact of well-known risk factors for such disorders (stress, biological sex, anxiety-related dispositions) on fear generalization will be examined. Findings from this study may provide insight into how these risk factors influence the development and/or maintenance of psychological disorders that involve overgeneralization of fear and could facilitate future approaches to their treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2019
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 18, 2018
CompletedFirst Posted
Study publicly available on registry
December 26, 2018
CompletedStudy Start
First participant enrolled
January 25, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2022
CompletedResults Posted
Study results publicly available
March 23, 2023
CompletedMarch 23, 2023
February 1, 2023
3.4 years
December 18, 2018
December 16, 2022
February 23, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Fear-potentiated Startle Responses to the CS+ and CS- During Acquisition
Peak eyeblink startle responses 20-200 ms following presentation of a startle probe were measured. Startle responses were assessed for each of 3 trial types: (1) following the startle probe alone \[noise alone (NA) trials\], (2) following the CS+ and startle probe (CS+ trials), and (3) following the CS- and startle probe (CS- trials). Participants were exposed to 16 blocks of trials, and each block included 1 presentation of each trial type. During the last 12 blocks, CS+ trials also included the presentation of an aversive US. For each block, startle responses to NA trials were subtracted from startle responses to CS+ trials and from startle responses to CS- trials to create 2 separate fear-potentiated startle response measures: 1 for the CS+ and 1 for the CS-. Average fear-potentiated startle responses to the CS+ and CS- during the last 4 blocks of trials were used as an indicator of fear learning (greater responses to the CS+, relative to the CS-, indicated greater learning).
Average of the responses from trial block 13, trial block 14, trial block 15, and trial block 16 on Day 1
EMG Responses to CS+, CS-, and Generalization Stimuli During Generalization Testing
Peak eyeblink startle responses 20-200 ms following the presentation of a startle probe were measured. Startle responses were assessed for each of 10 trial types: (1) following the startle probe alone \[noise alone (NA) trials\], (2) following the CS+ and startle probe (CS+ trials), (3) following each of 7 generalization stimuli and startle probe (GS trials), and (4) following the CS- and startle probe (CS- trials). Participants were exposed to 3 blocks of trials, and each block included 1 presentation of each trial type. For each block, startle responses to the NA trials were subtracted from startle responses to the CS+, GSs, and CS- trials to create separate fear-potentiated startle response measures for each of the 9 different stimuli. Average fear-potentiated startle responses to each stimulus across all 3 blocks were used as an indicator of fear expression. Greater scores for the generalization stimuli (GS) indicated a greater generalization of fear.
Average of responses from all trials on Day 2
Skin Conductance Responses to CS+ and CS- During Acquisition
Electrodermal activity was measured following presentation of the CS+ and CS- during acquisition on Day 1. Participants were exposed to 16 blocks of trials, with each block including a single presentation of each stimulus. During the last 12 blocks, CS+ trials included the presentation of an aversive US. For each block, skin conductance responses were quantified by calculating the average increase in electrodermal activity (from a 1 s pre-stimulus baseline) 3-6 s after CS+ or CS- onset. Average skin conductance responses to the CS+ and CS- during the last 4 blocks of trials were used as an indicator of fear learning (greater responses to the CS+, relative to the CS-, indicated greater learning).
Average of the responses from trial block 13, trial block 14, trial block 15, and trial block 16 on Day 1
Skin Conductance Responses to CS+, Generalization Stimuli, and CS- During Generalization Testing
Electrodermal activity was measured following presentation of the CS+, 7 generalization stimuli (GSs), and CS- during generalization testing on Day 2. Participants were exposed to 3 blocks of trials, with each block including a single presentation of each stimulus. For each block, skin conductance responses were quantified by calculating the average increase in electrodermal activity (from a 1 s pre-stimulus baseline) 3-6 s after onset of the CS+, 7 GSs, or CS- onset.. Average skin conductance responses to each stimulus across all 3 blocks were used as an indicator of fear expression. Greater scores for the generalization stimuli (GS) indicated a greater generalization of fear.
Average of responses from all trials on Day 2
US Expectancy Ratings to CS+ and CS- During Acquisition
Participants were exposed to 16 blocks of trials, and each block included 1 presentation of the CS+ and one presentation of the CS-. During the last 12 blocks, CS+ trials included the presentation of an aversive US. During each trial, participants pressed, within 3 seconds of stimulus onset, a button marked "+" if they expected the stimulus to be followed by the US, a button marked "-" if they did not expect the stimulus to be followed by the US, or a button marked "0" if they were uncertain. For the purpose of data analysis, + was scored as +1, - were scored as -1, and 0 was scored as 0. Average expectancy ratings during the last 4 blocks of trials were used as an indicator of fear learning (greater responses to the CS+, relative to the CS-, indicated greater learning).
Average of the ratings from trial block 13, trial block 14, trial block 15, and trial block 16 on Day 1
US Expectancy Ratings to CS+, CS-, and Generalization Stimuli During Generalization Testing
Participants were exposed to 3 blocks of trials, and each block included 1 presentation of the CS+, one presentation of each of 7 generalization stimuli (GSs), and one presentation of the CS-. Participants were instructed to press, within 3 seconds of stimulus onset, a button marked "+" if they expected the stimulus to be followed by the US, a button marked "-" if they did not expect the stimulus to be followed by the US, or a button marked "0" if they were uncertain. For the purpose of data analysis, + was scored as +1, - was scored as -1, and 0 was scored as 0. Average expectancy ratings for each stimulus across all 3 blocks were used as an indicator of fear. Greater scores for the generalization stimuli (GS) indicated a greater generalization of fear.
Average of ratings from all trials on Day 2
Secondary Outcomes (6)
Change in Baseline Salivary Cortisol (Nmol/l)
Day 1 (change from baseline to 25 min post-stress)
Change in Baseline Salivary Alpha-amylase (U/ml)
Day 1 (change from baseline to immediately after stress)
Average Subjective Pain, as Assessed by Verbal Self Report
Stress or sham control condition on Day 1
Average Subjective Stress, as Assessed by Verbal Self Report
Stress or sham control condition on Day 1
Change in Heart Rate (Bpm)
Day 1 (change from baseline to during stress or sham control manipulation)
- +1 more secondary outcomes
Other Outcomes (6)
Salivary Estradiol (pg/ml)
Average across Day 1 (baseline) and Day 2 (baseline)
State Anxiety
Day 2 - following generalization testing
Childhood Trauma Questionnaire (CTQ)
Day 2 - following generalization testing
- +3 more other outcomes
Study Arms (8)
Stress, immediate, males
EXPERIMENTALStress immediately before learning in males
Stress, delayed, males
EXPERIMENTALStress 30 minutes before learning in males
Sham control, immediate, males
SHAM COMPARATORSham control immediately before learning in males
Sham control, delayed, males
SHAM COMPARATORSham control 30 minutes before learning in males
Stress, immediate, females
EXPERIMENTALStress immediately before learning in females
Stress, delayed, females
EXPERIMENTALStress 30 minutes before learning in females
Sham control, immediate, females
SHAM COMPARATORSham control immediately before learning in females
Sham control, delayed, females
SHAM COMPARATORSham control 30 minutes before learning in females
Interventions
Male participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
Male participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
Male participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
Male participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
Female participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
Female participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
Female participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
Female participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
Eligibility Criteria
You may qualify if:
- years of age
- Registered student at Ohio Northern University in Ada, Ohio
You may not qualify if:
- Regular use of tobacco or recreational drugs (e.g., marijuana, cocaine, heroin, etc.)
- Previous diagnosis of Raynaud's disease or peripheral vascular disease
- Previous diagnosis of skin diseases (e.g., severe psoriasis, eczema, scleroderma)
- History of syncope or vasovagal response to stress
- History of any heart conditions or cardiovascular issues (e.g., high blood pressure)
- History of severe head trauma
- Current treatment with narcotics, beta-blockers, or steroids
- Previous diagnosis of substance use disorder
- Regular nightshift work
- Hearing loss
- Consumed alcohol in past 24 hours
- Engaged in strenuous exercise in past 24 hours
- Ate or drank anything but water in past 2 hours
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ohio Northern University
Ada, Ohio, 45810, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Phillip Zoladz
- Organization
- Ohio Northern University
Study Officials
- PRINCIPAL INVESTIGATOR
Phillip Zoladz, Ph.D.
Ohio Northern University
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 18, 2018
First Posted
December 26, 2018
Study Start
January 25, 2019
Primary Completion
June 30, 2022
Study Completion
June 30, 2022
Last Updated
March 23, 2023
Results First Posted
March 23, 2023
Record last verified: 2023-02
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- Data were shared on a semi-annual basis, beginning in January 2020.
- Access Criteria
- NIMH Data Archive
Raw data and data from descriptive/raw measures were submitted on a semi-annual basis to the NIMH Data Archive